CSL (ASX:CSL) share price wobbles on COVID vaccine news

The CSL Limited (ASX: CSL) share price is on watch after the UK found "possible links" between the AstraZeneca vaccine and blood clots.

| More on:
A man looking sheepish grits his teeth and looks to the side

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is a little wobbly this morning after negative vaccine news overnight from the United Kingdom.

The pharmaceutical giant, which produces and supplies the AstraZeneca PLC (LSE: AZ) COVID-19 vaccine in Australia, is trading close to its opening price after news that the UK medical regulator has found a "possible link" between the vaccine and blood clotting in younger adults. The regulator noted that blood clotting was considered a rare side-effect of the vaccine.

At the time of writing, the CSL share price is trading flat around $263 as Australian investors digest the news out of the UK.

What's driving the CSL share price?

The Medicines and Healthcare products Regulatory Agency (MHRA) released a statement overnight concluding the evidence of a causal link between blood clotting and receiving the AstraZeneca vaccine in low platelet individuals was stronger than previously thought, but not conclusive.

The agency said the risk of blood clotting decreased with age and was "extremely rare and unlikely to occur". 

Its statistics suggested the risk of developing a blood clot after the first vaccine dose was 1 in 250,000 (0.0004%) and the risk of a fatal blood clot was 1 in 1 million (0.0001%). Despite this, the UK will provide alternative vaccines to the under 30s if possible.

The World Health Organisation (WHO) responded to the UK news, saying evidence of the link, while plausible, was not yet confirmed. It also noted the risk of catching and dying from COVID-19 was much higher than the risk of the vaccine.

What did our top doctor say?

Australia's chief medical officer, Professor Paul Kelly told ABC Radio:

There seems to be a trend in younger people and, at least in the European data in women being more common, but I would really stress these are extremely rare events and like with any treatment… we have to look at the risk and benefit.

And we do know that the benefits of vaccinations against this very serious diseases Covid is a really important component of our control…

Ultimately it will be a decision by the Australian Government about what that means for the vaccine rollout.

Australia's position

Australia is primarily relying on the AstraZeneca vaccine in the fight against COVID. The government has contracted CSL to develop the vaccine locally.

Both the imported and locally manufactured AstraZeneca vaccine have already been approved by the Therapeutics Good Administration (TGA).

Speaking about the developments this morning, Prime Minister Scott Morrison said Australia's medical experts would look at the data before making new recommendations to the government.

The Prime Minister also stressed the extremely low chances of people experiencing blood clotting from the vaccine. He advised that at present, the vaccine rollout would not be affected by the latest developments.

Motley Fool Australia reached out to CSL for comment, but none was received before publication.

Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A view of competitors in a running event, some wearing number bibs, line up together on a starting line looking ahead as if to start a race.
Technology Shares

Here's how the ASX 200 market sectors stacked up last week

ASX technology shares led the market with a 2.48% increase last week.

Read more »

A father helps his son look through binoculars during a family holiday or day out in the city.
Opinions

Up 190% in a year, why I think Life360 shares can keep soaring higher

This tech stock has plenty of potential.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »

Magnifying glass on a rising interest rate graph.
Share Market News

Will the RBA finally cut interest rates next week?

Let's see what economists are saying about the central bank's meeting.

Read more »

A couple sits on a sofa, each clutching their heads in horror and disbelief, while looking at a laptop screen.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors endured a rough Friday to close the trading week today.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Broker Notes

7 ASX All Ords shares elevated to 'strong buy' status in October

The brokers turned bullish on these ASX companies last month.

Read more »

A businessman compares the growth trajectory of property versus shares.
Share Market News

How ASX shares vs. property performed in October

The national home value rose for the 21st consecutive month while the ASX 200 dipped.

Read more »

Person with thumbs down and a red sad face poster covering the face.
Share Fallers

The worst 3 ASX 200 stocks to buy and hold in October unmasked

You would have done well to avoid these three ASX 200 stocks in October.

Read more »